Phase I clinical trial of Zevalin (90Y-ibritumomab) in patients with B-cell non-Hodgkin's lymphoma (NHL) with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation (ASCT).

被引：0
|
作者：
Vose, JM
Bierman, PJ
Lynch, JC
Bociek, GR
Multani, PS
Armitage, JO
机构：
[1] IDEC Corp, San Diego, CA USA
[2] Univ Nebraska, Med Ctr, Omaha, NE USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
92
引用
收藏
页码：30A / 30A
页数：1
相关论文
共 50 条
  • [1] Phase I trial of 90Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation
    Vose, Julie M.
    Bierman, Philip J.
    Loberiza, Fausto R., Jr.
    Bociek, Robert G.
    Matso, Daniel
    Armitage, James O.
    LEUKEMIA & LYMPHOMA, 2007, 48 (04) : 683 - 690
  • [2] Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)
    Swinnen, L. J.
    Flinn, I. W.
    Kahl, B. S.
    Frey, E.
    Rogers, K.
    Jung, M.
    Jacene, H.
    Wahl, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Dose finding trial of Yttrium 90 ibritumomab tiuxetan (90YIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Flinn, I. W.
    Kahl, B. S.
    Frey, E. C.
    Bianco, J. A.
    Hammes, R. J.
    Webb, J.
    Swinnen, L. J.
    Sgouros, G.
    Wahl, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 430S - 430S
  • [4] Dose finding trial of yttrium 90 (90Y) ibriturnomab tiuxetan with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
    Flinn, IW
    Kahl, BS
    Frey, E
    Bianco, JA
    Hammes, RJI
    Billing, LS
    Swinnen, LJ
    Sgouros, G
    Wahl, RL
    BLOOD, 2004, 104 (11) : 256A - 256A
  • [5] Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in the treatment of non-Hodgkin's lymphoma (NHL):: Incorporation into autologous stem cell transplantation (ASCT) regimens
    Nademanee, A
    Krishnan, A
    Fung, H
    Raubitschek, A
    Forman, S
    Molina, A
    ANNALS OF ONCOLOGY, 2005, 16 : 100 - 100
  • [6] Yttrium-90 ibritumomab tiuxetan combined with high-dose beam chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Scheid, C.
    Huebel, K.
    Boldt, F.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    ANNALS OF ONCOLOGY, 2008, 19 : 241 - 242
  • [7] Yttrium-90 ibritumomab tiuxetan combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma
    Shimabukuro-Vornhagen, A.
    Josting, A.
    Huebel, K.
    Scheid, C.
    Dietlein, M.
    Engert, A.
    Schnell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] High-dose sequential chemotherapy (HDSC) in support of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL)
    Oyan, B
    Koc, Y
    Ozdemir, E
    Kansu, E
    BLOOD, 2004, 104 (11) : 393B - 393B
  • [9] Multicenter phase II trial of 90Y-Ibritumomab tiuxetan with high-dose chemotherapy (busulfan/cyclophosphamide/etoposide) followed by autologous stem cell transplantation in relapsed, refractoried, or high-risk B-cell NHL
    Kang, Byung Woog
    Jo, Jae-Cheol
    Kim, Shin
    Jang, Geundoo
    Lee, Sung Sook
    Sym, Sun Jin
    Ryu, Jin-Sook
    Kim, Won Seog
    Yoon, Sung Soo
    Suh, Cheolwon
    BLOOD, 2007, 110 (11) : 569A - 569A
  • [10] Multicentre phase II trial of 90Y-ibritumomab tiuxetan with high-dose chemotherapy (busulfan/cyclophosphamide/etoposide) followed by autologous stem cell transplantation in relapsed, refractory, or high-risk B-cell NHL
    Kang, B. W.
    Kim, S.
    Cho, Y. H.
    Ryu, J. -S.
    Kim, W. S.
    Yoon, S. S.
    Suh, C.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S248 - S248
12345